Heart failure & cardiomyopathies
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Authors' conclusion
Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction.
Study context
- Population
- Patients hospitalised for acute MI at risk for heart failure (HF) (new LVEF <45% or signs/symptoms of congestion)
- Participants
- 6,522 patients
- Comparison
- Empagliflozin vs placebo
- Primary endpoint
- First HF hospitalisation and total HF hospitalisations
- Follow-up
- Median 17.9 months
Methodological detailsdouble-blind, placebo-controlled, event-driven, prespecified secondary analyses
- Double-blind
- Placebo-controlled
- Event-driven
- Prespecified secondary analyses
Primary result
As reported in the abstract
First HF hospitalisation; total HF hospitalisations · median 17.9 months
Empagliflozin vs PlaceboEstimate (95% CI)P value
First HF hospitalisation
HR 0.77(0.60–0.98)
P = 0.031Total HF hospitalisations
rate ratio 0.67(0.51–0.89)
P = 0.006Further findings
First and total HF hospitalisations, by subgroup
- Consistent empagliflozin benefit across clinically relevant subgroups
New use of diuretics, renin-angiotensin modulators or MRA after discharge
- Less with empagliflozin vs placebo
- all P<0.05
Original publication
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. Published 6 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →